New combo attack on tough pancreatic cancer

NCT ID NCT04926467

Recruiting now Disease control Sponsor: Baylor Research Institute Source: ClinicalTrials.gov ↗

Summary

This study is testing if adding a drug called anakinra to standard chemotherapy helps control pancreatic cancer better. Anakinra targets inflammation, which is thought to help the cancer grow. The trial is for people whose cancer might be removable by surgery. Patients receive the drug combination before and after their operation to see if it improves outcomes.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Baylor University Medical Center, Charles A Sammons Cancer Center
RECRUITING

Dallas, Texas, 75246, United States

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PANCREATIC ADENOCARCINOMA